Skip to main content

BIRC2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2.

Be the first to review this product! Submit a review

Images

Western blot - Human BIRC2 (cIAP1) knockout HeLa cell line (AB265896), expandable thumbnail
  • Sanger Sequencing - Human BIRC2 (cIAP1) knockout HeLa cell line (AB265896), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2

Alternative names

API 1, Apoptosis inhibitor 1, BIRC2_HUMAN, Baculoviral IAP repeat containing 2, Baculoviral IAP repeat-containing protein 2, C-IAP1, Cellular inhibitor of apoptosis 1, HIAP-2, IAP homolog B, IAP-2, Inhibitor of apoptosis protein 2, MIHB, NFR2 TRAF signalling complex protein, RING finger protein 48, RNF 48, TNFR2-TRAF-signaling complex protein 2, cellular inhibitor of apoptosis protein 1

Recommended products

BIRC2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 2
Antibiotic resistance
Puromycin 1µg/mL
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
BIRC2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

The cellular inhibitor of apoptosis protein 1 (cIAP1) also referred to as BIRC2 is a protein with a molecular mass of approximately 70 kDa. cIAP1 belongs to the inhibitor of apoptosis (IAP) family and contains several distinct domains important for its function including three Baculoviral IAP Repeat (BIR) domains a ubiquitin-associated (UBA) domain and a really interesting new gene (RING) domain. This protein is expressed in various tissues but predominantly in cells engaged in apoptosis regulation such as immune cells.

Biological function summary

CIAP1 plays an important role in regulating apoptosis by inhibiting the activity of certain caspases including caspase-3 and caspase-7. It is often part of larger protein complexes that include other members of the IAP family such as cIAP2. By binding directly to tumor necrosis factor receptor-associated factors (TRAFs) cIAP1 helps modulate signaling pathways that determine cell survival or death contributing to cellular homeostasis.

Pathways

CIAP1 is intricately involved in the NF-κB signaling pathway and the TNF receptor signaling pathway. Its interaction with TRAFs links it to these critical pathways helping to control inflammatory and immune responses. Other proteins related to cIAP1 through these pathways include RIP1 and TRAF2 both important for transmitting signals that affect cell fate decisions.

Associated diseases and disorders

CIAP1 has significant implications in cancer and autoimmune disorders. In many cancers overexpression of cIAP1 contributes to uncontrolled cell proliferation by preventing apoptosis therefore aiding tumor survival and progression. Moreover its dysregulation is linked to disorders such as rheumatoid arthritis where improper cell death regulation leads to tissue damage. cIAP1 interacts with and regulates the activity of the protein XIAP in contributing to these diseases making it a potential target for therapeutic interventions.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com